Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study

Documenti analoghi

• Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
  di: Isla M. Johnson, et al.
  Pubblicazione: (2024)
• Inflammatory disorders in IDH‐mutated myeloid neoplasms: Characteristics and response to IDH inhibitors
  di: Romain Stammler, et al.
  Pubblicazione: (2025)
• Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
  di: Dian Jin, et al.
  Pubblicazione: (2024)
• The heart of VIALE‐A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia
  di: Shyam A. Patel
  Pubblicazione: (2024)
• Hypomethylating agent and venetoclax are effective salvage therapies in relapsed/refractory early T‐cell precursor acute lymphoblastic leukaemia
  di: Vaibhav Agrawal, et al.
  Pubblicazione: (2025)